PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO

PDS Biotechnology ( (PDSB) ) has shared an update.

On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® HPV abstracts on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts detail studies presented during the Head and Neck Cancer Poster Session from May 30 to June 3, 2025, in Chicago, Illinois. The data from the VERSATILE-002 trial showed a median overall survival of 30.0 months for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, indicating durable clinical responses. The trial’s results highlight the potential impact on treatment strategies for this rapidly growing patient population, positioning PDS Biotech as a significant player in addressing HPV16-positive head and neck cancers.

The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers.

Average Trading Volume: 577,214

Technical Sentiment Signal: Sell

Current Market Cap: $63.08M

Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.